期刊文献+

肿瘤基因治疗载体在临床应用中的问题和研究进展 被引量:3

The problem and progress of gene therapy vectors of tumor in clinical application
暂未订购
导出
摘要 构建安全、有效、可控的载体为肿瘤基因治疗的瓶颈。肿瘤基因治疗载体分为病毒性载体和非病毒性载体。肿瘤基因治疗载体在临床应用中尚存在许多问题,目前的趋势集中于安全性、高效性、靶向特异性和多功能基因联合研究。 It is critical to construct safe, efficient and controllable vectors in gene therapy of tumor. The vectors available include viral and non-viral vectors. However, there are numerous problems to be solved. The current progresses focus on studies of safety, high efficiency and combination of multifunctional gene.
作者 楚雍烈 答嵘
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2006年第4期313-318,共6页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 肿瘤 基因治疗 载体 tumor gene therapy vectors
  • 相关文献

参考文献35

  • 1Weber W,Fussenegger M.Pharmacologic transgene control systems for gene therapy[J].J Gene Med,2006,8(5):533-534.
  • 2Buchschacher GL.Introduction to retroviruses and retroviral vectors[J].Somat Cell Mol Genet,2001,26(1):1-11.
  • 3George JA.Gene therapy progress and prospects:adenoviral vectors[J].Gene Ther,2003,10(6):1135-1141.
  • 4James B,Wechuck,Ozuer A,et al.Effect of temperature,medium composition,and cell passage on production of herpesbased viral vectors[J].Biotech and Bioengin,2002,79(1):112-119.
  • 5Monahan PE,Samulski RJ.Adeno-associated virus vectors for gene therapy:more pros than cons[J].Mol Med Today,2000,6(2):433-440.
  • 6Roth JA,Cristiano RJ.Gene therapy for cancer:what have we done and where are we going[J].J Natl Cancer Inst,1997,89(1):21-39.
  • 7Gomez-Navarro J,Curiel DT,Douglas JT.Gene therapy for cancer[J].Eur J Cancer,1999,35(3):867-885.
  • 8Hitt MM,Gauldie J.Gene vectors for cytokine expression in vivo[J].Curr Pharm Des,2000,6(3):613-632.
  • 9Mountain A.Gene therapy:the first decade[J].Trends Biotechnol,2000,18(1):119-128.
  • 10Romano G,Michell P,Pacilio C,et al.Latest developments in gene transfer technology:achievements,perspectives,and controversies over therapeutic applications[J].Stem Cells,2000,18(1):19-39.

同被引文献32

  • 1刘铁连,张海锋,杨吉成.候选抑癌基因ING4的研究进展[J].中国现代药物应用,2007,1(3):69-72. 被引量:2
  • 2唐海英,郑金平,陈显久,解军.内源性血管生成抑制因子Arresten的序列测定及在E.coli BL21中的表达[J].中国药物与临床,2007,7(6):410-412. 被引量:1
  • 3Zhang Y, Dai X M, David F. Kallmes, et al. Synthesis of a technetium-99m-labeled thymidine analog: a potential HSV,-TK substrate for non-invasive reporter gene expression imaging[J]. Tetrahedron Letters, 2004(45): 8673-8676.
  • 4Lee KA, Cho K J, Kim S H, et al. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on theIL-18-mediated immune response[J]. Cancer Letters, 2005, 229 (2): 261-270.
  • 5Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for cancer gene therapy of chemically induced rat mammary tumors[J]. Breast Cancer Res Treat, 2001, 66(2): 165-170.
  • 6Nakamura T, Sasaki T, Fujimori M, et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and applica- tion to enzyme/pro-drug therapy of hypoxic solid tumors[J]. Biosci Bio Technol Biochem, 2002, 66(11): 2362-2366.
  • 7Bolotin A, Wincker P, Mauger S, et al. The complete genome sequence of the lactic acid bacterium Ixtctococcus lactis ssp. lactis IL1403[J]. Genome Research, 2001, 11: 731-753.
  • 8Morello E, Bermudez-humaran L G, Llull D, et al. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion[J]. Journal of Molecular Microbiology and Biotech- nology, 2008, 14: 48-58.
  • 9Mifune J, Grage K, Rehm B H. Production of functionalized bio- polyester granules by recombinant Lactococcus lactis[J]. Applied and Environmental Microbiology, 2009, 75(14): 4668-4675.
  • 10HoLo H, Nes I F. High-frequency transformation by electropota- tion of Lactococus lactis subsp. Cremoris growth with glycine in osmotically stabilized media[J]. Applied and Environmental Micro- biology, 1989, 55(12): 3119-3123.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部